Compare XENE & DLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XENE | DLB |
|---|---|---|
| Founded | 1996 | 1965 |
| Country | Canada | United States |
| Employees | 370 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.8B |
| IPO Year | 2014 | 2004 |
| Metric | XENE | DLB |
|---|---|---|
| Price | $54.29 | $54.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $68.55 | ★ $90.75 |
| AVG Volume (30 Days) | ★ 803.9K | 764.8K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.54 |
| Revenue | ★ $311,000.00 | N/A |
| Revenue This Year | N/A | $6.22 |
| Revenue Next Year | $2,496.48 | $3.84 |
| P/E Ratio | ★ N/A | $35.01 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.19 | $52.45 |
| 52 Week High | $62.91 | $76.91 |
| Indicator | XENE | DLB |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 33.23 |
| Support Level | $52.92 | N/A |
| Resistance Level | $59.43 | $68.75 |
| Average True Range (ATR) | 1.67 | 1.70 |
| MACD | -0.31 | -0.36 |
| Stochastic Oscillator | 23.98 | 24.78 |
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.